comprehensive -WSS

comprehensive

author：fashion 2025-08-25 16:35:02 - browse：8523

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： New oral drug delivery patch is modeled after octopus tentacles

leisure time

explore

WSS

Bill would stop addiction treatment from triggering child abuse inquiry

CRISPR base editing slashes cholesterol levels in monkeys

RSV injection headlines need to be accurate for good uptake

CDC picks Alphabet's Verily for wasterwater surveillance contract

3 questions for the future of Biden's cancer moonshot

Chan Zuckerberg Biohub Chicago to focus on inflammation

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Activists slam private health insurers over coverage restrictions

IVG is promising — but it won’t replace IVF quite yet

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Tori Bowie and the unacceptable rates of Black maternal death

Chan Zuckerberg Biohub Chicago to focus on inflammation

Virginia high school admissions case could be legal follow

Will an HIV vaccine ever be a reality?

State Dept. review finds Biden bears some blame for Afghanistan failures

Physician executives need more than on

focus

Congress extends some pandemic preparedness programs

Why age limits for politicians are a terrible idea

Chemotherapy drug shortage eases slightly but still widespread

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

What will Novo Nordisk's VC do with its influx of cash?

The United States is paying nearly triple for new Covid vaccines

leisure time

focus

explore

hotspot